Former Apple Health clinical lead joins BlinkLab board ahead of FDA push
BlinkLab Limited (ASX: BB1) has appointed Dr Raphael Bernier, former Clinical Lead for Mental Health at Apple Health, as a Non-Executive Director, effective immediately. The appointment arrives as the company targets FDA 510(k) submission for its BlinkLab Dx1 autism diagnostic aid in Q1 CY 2027, with an FDA clearance response targeted in Q2 CY 2027.
This is a deliberate board-strengthening move timed to BlinkLab’s most consequential regulatory period to date, not a routine governance update.
When big ASX news breaks, our subscribers know first
Who is Dr Raphael Bernier?
Dr Bernier’s credentials span Big Tech, elite academic medicine, and front-line autism clinical care:
- Led clinical development of Apple’s Mental Wellbeing app for iPhone, iPad and Apple Watch; also conducted early-stage research across released and unreleased Apple ecosystem products
- Former Executive Director, Seattle Children’s Autism Center, one of the largest autism clinical programs in the United States, serving thousands of patients each year
- Former William J. and Lydia N. Gumerman Endowed Chair in Child Psychiatry, University of Washington
- Former Associate Director, University of Washington Center on Human Development and Disability
- Authored more than 200 scientific articles and two books; cited more than 36,000 times
- Principal or co-investigator on more than 40 studies funded by the U.S. National Institutes of Health (NIH) and foundations, focused on the causes and neuroscience of autism and related neurodevelopmental disorders
- PhD from the University of Washington; clinical training at UCLA; also holds degrees from the University of Wisconsin and Tufts University
- Currently faculty, Department of Psychology, University of Washington; remains an active clinician
Dr Raphael Bernier, Non-Executive Director
“I’m so very delighted to join BlinkLab. The strong scientific foundation and innovation underlying BlinkLab’s approach ensures a meaningful impact on children and families throughout the world. There is nothing more exciting and rewarding for me than being a part of that.”
Why this appointment matters for the U.S. commercialisation pathway
Dr Bernier’s appointment addresses specific, real-world barriers to autism diagnosis and digital health adoption in the United States. Four dimensions stand out for investors:
- Clinical workflow depth: As former head of one of the largest autism clinical programs in the US, Dr Bernier brings direct understanding of diagnostic workflows, specialist capacity constraints, and waiting-list pressures that BlinkLab Dx1 is designed to reduce.
- Digital product translation: His Apple Health tenure demonstrated the ability to translate rigorous clinical science into scalable digital products deployed at a global consumer level.
- Network reach: Dr Bernier’s relationships across autism care, research institutions, health systems, and technology are expected to support BlinkLab’s engagement with key opinion leaders, product development, implementation planning, and preparation for responsible commercial adoption.
- Board capability: The board’s expertise now spans clinical practice, AI and digital health, and Big Tech product commercialisation, directly ahead of a specialist-first U.S. launch that is subject to FDA clearance.
BlinkLab’s current corporate timetable for BlinkLab Dx1 in the United States is as follows:
| Milestone | Target Timing |
|---|---|
| Pivotal U.S. study completion | Q4 CY 2026 |
| FDA 510(k) submission | Q1 CY 2027 |
| FDA 510(k) clearance response | Q2 CY 2027 |
| Specialist-first U.S. commercial launch | Subject to clearance |
Brian Leedman, Non-Executive Chairman
“Raphael brings an exceptional combination of clinical insight, research leadership and commercial product experience. His recent work at Apple Health gives him a valuable perspective on translating rigorous clinical science into digital products that can be deployed at scale…”
What is FDA 510(k) clearance — and why does it matter for BlinkLab investors?
The FDA 510(k) is a premarket submission process through which a medical device manufacturer demonstrates that its product is substantially equivalent to a device already cleared by the FDA. It is the standard regulatory pathway for digital diagnostic aids and AI-assisted clinical tools.
For BlinkLab, 510(k) clearance is a prerequisite for any commercial launch in the United States, the world’s largest healthcare market. BlinkLab Dx1 is a smartphone-based autism diagnostic aid for clinicians that uses artificial intelligence and reflex-based measures to support earlier and more accurate autism identification. Without clearance, the company cannot commercially deploy the product to U.S. clinicians, making the FDA timeline the single most material near-term milestone for the business.
Peer-reviewed validation in a Q1-ranked journal, based on a 536-child multi-centre study, preceded the pivotal trial launch and demonstrated that the smartphone platform can objectively detect autism-related sensorimotor differences, strengthening the evidentiary foundation underpinning the FDA submission.
The pivotal FDA 510(k) validation study commenced in March 2026 across 10 leading US clinical sites, including Cincinnati Children’s Hospital, Seattle Children’s Hospital, and Vanderbilt Kennedy Center, with participant recruitment expected to complete within approximately 8 months.
Board transition — Dr Richard Hopkins steps down
Concurrent with Dr Bernier’s appointment, Dr Richard Hopkins has stepped down as Non-Executive Director. Dr Hopkins served on the BlinkLab board since May 2022, contributing his experience in biotechnology leadership, corporate strategy, financing, business development, and intellectual property across a significant period of company growth, including BlinkLab’s ASX listing and the development and execution of its U.S. clinical and regulatory strategy.
The board acknowledged Dr Hopkins’ service and counsel throughout this formative period for the company.
Dr Bernier’s remuneration terms
The material terms of Dr Bernier’s engagement are as follows:
- Base remuneration: A$100,000 per annum (excluding GST)
- Performance rights: 1,500,000 total, comprising two equal classes:
- 750,000 Class A Performance Rights: vest on FDA approval of the company’s smartphone-based autism diagnostic product plus 12 months of continuous service from commencement date, on or before three years from the date of issue
- 750,000 Class B Performance Rights: vest on FDA approval plus 24 months of continuous service from commencement date, on or before three years from the date of issue
The performance rights structure directly ties Dr Bernier’s equity upside to FDA clearance, aligning his incentives with the regulatory milestone that investors are most closely watching.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already getting the edge on market-moving announcements the moment they drop. Click the “Free Alerts” button at Big News Blast to stay ahead of the next big move.